System and method of modeling erythropoiesis and its management

US10319478B2 · kind B2 · utility

Assignee

• Fresenius Medical Care Holdings, Inc. · US

Inventors

• Doris H. Fuertinger · New York, US
• Franz Kappel · Graz, AT
• Peter Kotanko · New York, US
• Nathan W. Levin · New York, US
• Stephan Thijssen · New York, US

Key dates

• Filing date: Sep 7, 2012
• Grant date: Jun 11, 2019
• Expiry date: Jul 14, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G16H20/17
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, and employing the patient parameters and an initially selected EPO administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen. Optionally, if the patient's hematocrit and/or hemoglobin concentration is not predicted by the model to be in the desired range at the predetermined time, the method includes employing the model with one or more different ESA administration regimens until the model predicts that the patient's hematocrit and/or hemoglobin concentration will be in the desired range at the predetermined time. The method then includes administering ESA to the patient with an ESA administration regimen predicted to adjust the patient's hematocrit and/o…